CBD Brands Initiates AD study

December 2, 2019
CBD Brands Initiates AD study image

The FDA recently cracked down on the safety of CBD products.

In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD).

The study aims to provide a preliminary assessment of the safety and efficacy of proprietary CBD-infused lotion as an AD treatment. It is a double-blinded, placebo-controlled study that will seek to enroll h 90 subjects. The subjects will receive one of three formulations including a placebo.

The FDA recently warned that CBD can be harmful and that this harm can be insidious. CBD can cause liver injury and affect the metabolism of other drugs, causing serious side effects. Moreover, the use of CBD with alcohol or other Central Nervous System depressants increases the risk of sedation and drowsiness, which can lead to injuries, the group states.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free